Blue Owl Capital Inc. ("Blue Owl") today reported its financial results for the fourth quarter ended December 31, 2024. "2024 was a year of new highs for Blue Owl ? we reported record fundraising and ...

Inc. today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in partnership with Bristol Myers Squibb (BMS). "We are pleased to see Abecma expansion in the third ...